摘要
Dear Editor,The severe coronavirus disease 2019(COVID-19)is associated with coagulopathy.Anticoagulants,such as low-molecular-weight heparin,warfarin,thrombin inhibitors,and factor Xa(FXa)inhibitors,are thus recommended by the American Society of Hematology and National Institutes of Health for COVID-19 patients(Wenzler et al.,2020;Adam et al.,2021).Clinical trials with anticoagulants have shown the increased survival of critically ill COVID-19 patients under non-invasive and invasive ventilatory assistance(Wenzler et al.,2020;Adam et al.,2021),along with decreased consumption of platelets and clotting factors and a reduced risk of hemorrhage(Adam et al.,2021).Among the anti-clotting agents,early use of orally available FXa and thrombin inhibitors(Chowdhury et al.,2020;Rentsch et al.,2021)prevented high levels of D-dimer,which is the final product from the clotting/fibrinolysis cascade and is directly implicated with severe COVID-19(Rentsch et al.,2021).
